Chartwell Investment Partners LLC lifted its stake in shares of Roche Holdings AG Basel ADR (OTCMKTS:RHHBY) by 8.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 107,023 shares of the company’s stock after buying an additional 8,732 shares during the quarter. Chartwell Investment Partners LLC’s holdings in Roche Holdings AG Basel were worth $4,636,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors also recently modified their holdings of the company. Tower Bridge Advisors raised its stake in Roche Holdings AG Basel by 0.4% during the first quarter. Tower Bridge Advisors now owns 107,959 shares of the company’s stock valued at $4,380,000 after buying an additional 410 shares in the last quarter. Cornerstone Investment Partners LLC boosted its holdings in Roche Holdings AG Basel by 12.1% in the first quarter. Cornerstone Investment Partners LLC now owns 6,326 shares of the company’s stock worth $257,000 after purchasing an additional 684 shares during the period. Arkadios Wealth Advisors bought a new stake in Roche Holdings AG Basel during the first quarter valued at $37,000. Bath Savings Trust Co raised its holdings in shares of Roche Holdings AG Basel by 11.4% during the second quarter. Bath Savings Trust Co now owns 9,329 shares of the company’s stock worth $405,000 after purchasing an additional 954 shares during the period. Finally, James Investment Research Inc. boosted its holdings in shares of Roche Holdings AG Basel by 1,353.4% in the 2nd quarter. James Investment Research Inc. now owns 1,061 shares of the company’s stock valued at $46,000 after buying an additional 988 shares during the period. Institutional investors and hedge funds own 0.30% of the company’s stock.
Shares of RHHBY stock opened at $43.10 on Friday. Roche Holdings AG Basel ADR has a 1 year low of $33.30 and a 1 year high of $46.63. The company has a current ratio of 1.30, a quick ratio of 1.04 and a debt-to-equity ratio of 0.35. The business’s fifty day moving average is $44.21 and its 200-day moving average is $42.63.
RHHBY has been the topic of several analyst reports. Sanford C. Bernstein started coverage on Roche Holdings AG Basel in a research report on Monday, July 13th. They issued an “outperform” rating on the stock. UBS Group reaffirmed a “buy” rating on shares of Roche Holdings AG Basel in a report on Wednesday. Wolfe Research raised shares of Roche Holdings AG Basel from a “market perform” rating to an “outperform” rating in a research note on Wednesday, May 13th. ValuEngine lowered shares of Roche Holdings AG Basel from a “sell” rating to a “strong sell” rating in a research note on Thursday, July 2nd. Finally, Barclays reaffirmed an “overweight” rating on shares of Roche Holdings AG Basel in a report on Friday, May 15th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $48.00.
Roche Holdings AG Basel Company Profile
Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, anticoagulation therapy, bone, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid and liver disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus and infectious diseases.
Further Reading: Why do corrections happen?
Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.